CLPT: Bullish Engulfing detected on 4 Jun 2026

CLPT is forming a bullish engulfing pattern with the stock at $13.30, just above key resistance at $13.58. Structure score of 15.0 indicates a well-defined pattern with clean support at $10.84 and resistance at $13.58. Volume score of 8.0 and breakout score of 5.0 suggest moderate confirmation — current volume of 733,204 shares is only 10% above the 20-day average. RSI at 63 indicates room to run higher without overbought conditions. The pattern emerged after a 3-month rally of 48.77%, and the stock now sits 60.82% above its 52-week low. Overall score of 74 reflects a mid-to-high quality setup with 55.65% historical win probability.

ClearPoint Neuro reported first quarter 2026 results on May 13, 2026, achieving record revenue with 25% organic device growth and 43% overall growth. Q1 2026 revenue of $12.1 million was up 43% year-over-year, with neurosurgery navigation revenue rising 80% and capital equipment up 177%. Gross margin improved to 64% with cash of $35.6 million, and 2026 revenue is estimated at $52–56 million. The activated installed base across all ClearPoint technology including IRRA flow systems now includes over 175 global centers. However, despite constructive fundamentals, four of the five earnings events saw double-digit percentage declines the next day, with an average next-day move of -8.82%. The bullish pattern is forming in the context of strong execution but a market that has historically sold off CLPT earnings announcements.

A successful bullish engulfing breakout above $13.58 would target $14.16 (conservative measured move), with volume confirmation needed above the recent 733K share level. The pattern invalidates below support at $10.84, representing a 18.6% downside risk from current levels. With a 55.65% historical win probability, the pattern suggests near-term upside potential but with roughly even odds of failure. Volume needs to sustain above average levels to confirm the breakout — low volume follow-through would weaken the setup's reliability. The beta of 1.97 indicates this high-volatility stock could amplify moves in either direction once the breakout is triggered.

Key risks include: (1) History of post-earnings selloffs — four of five recent earnings events saw double-digit percentage declines the next day, suggesting the market may struggle to sustain momentum despite strong results; (2) Elevated volatility with 20-day volatility at 80.13% and a beta of 1.97, creating significant intraday swings; (3) RSI at 63 approaches overbought territory, and the stock is up 48.77% in 3 months, raising pullback risk; (4) Modest volume confirmation (volume ratio 1.1x) means the breakout lacks strong conviction; (5) Medical device sector regime at 0.39 regime score indicates weak sector tailwinds despite broader bullish market conditions. Pattern reliability is moderate (55.65% win probability), so position sizing should reflect this.